| atezolizumab based treatment | pembrolizumab based treatment |
| atezolizumab plus nab-paclitaxel | atezolizumab plus paclitaxel | pembrolizumab plus SoC |
| mBC - TNBC - L1 - PDL1 positive 4 | | | |
Comparator:
vs Standard of Care (SoC); vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;